Fused thiazole derivatives as kinase inhibitors
US8242116B2 · kind B2 · utility
9Cited by
0References
7Claims
0Family size
Assignee
Inventors
- Rikki Peter Alexander
- Pavandeep Singh Aujla
- Karen Viviane Lucile Crepy
- Anne Marie Foley
- Richard Jeremy Franklin
- Alan Findlay Haughan
- Helen Tracey Horsley
- William Mark Jones
- Bénédicte Lallemand
- Stephen Mack
- Trevor Morgan
- Patrick Pasau
- David Jonathan Phillips
- Verity Margaret Sabin
- George Martin Buckley
- Kerry Jenkins
- Benjamin Perry
Key dates
| Filing date | Jun 26, 2007 |
| Grant date | Aug 14, 2012 |
| Priority date | — |
| Expiry date | Feb 3, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.